Severe Mental Illness — MCQs
On this page
A 27-year-old woman with bipolar affective disorder type I has been stable on lithium carbonate 800mg daily for 2 years. She attends for routine monitoring. Blood tests show: lithium level 0.7 mmol/L, TSH 8.5 mU/L (normal 0.5-5.0), free T4 11 pmol/L (normal 10-20), creatinine 95 μmol/L, eGFR >90 mL/min. She reports feeling more tired than usual but denies other symptoms. What is the most appropriate management?
A 38-year-old man with paranoid schizophrenia has been taking olanzapine 20mg daily for 5 years. He develops increasing social withdrawal, reduced self-care, and loss of motivation over 8 months. Mental state examination reveals flat affect, poverty of speech, and lack of volition. There are no positive psychotic symptoms. What is the most appropriate medication adjustment?
A 41-year-old woman with schizoaffective disorder has been maintained on depot paliperidone palmitate 150mg monthly for 3 years with good symptom control. She now presents requesting to try for pregnancy. Her mental state remains stable with no active psychotic symptoms. She has previously relapsed rapidly when antipsychotic medication was discontinued. What is the most appropriate advice regarding her medication management?
A 29-year-old man with bipolar affective disorder type I presents to the emergency department with a 2-day history of increasing confusion, fever (39.2°C), muscle rigidity, and profuse sweating. He was started on haloperidol 10mg twice daily 5 days ago for an acute manic episode. Observations show: BP 165/95 mmHg, HR 115 bpm, RR 22/min. Blood tests reveal: CK 8500 U/L, WCC 15.2 × 10⁹/L, creatinine 145 μmol/L. What is the most likely diagnosis?
A 36-year-old man with a 10-year history of bipolar affective disorder type I presents to his psychiatrist. He has had three previous manic episodes requiring hospitalisation. For the past 8 months, he has been stable on lithium carbonate 1200mg daily. His most recent lithium level was 0.9 mmol/L (therapeutic range 0.6-1.0). He now presents with a 4-day history of persistent vomiting and diarrhoea due to gastroenteritis. What is the most appropriate immediate management?
A 45-year-old woman with schizophrenia presents to the community mental health team. She has been taking quetiapine 750mg daily for 18 months with good symptom control. Blood tests reveal: HbA1c 58 mmol/mol, fasting glucose 7.8 mmol/L, total cholesterol 6.2 mmol/L, triglycerides 3.4 mmol/L. Her BMI has increased from 24 to 31 kg/m² since starting quetiapine. She has no cardiovascular symptoms. What is the most appropriate next step in management?
A 33-year-old woman with schizophrenia treated with risperidone 6mg daily for 2 years presents to her GP. She has gained 18kg in weight (BMI now 34 kg/m²) and her most recent blood tests show: fasting glucose 6.9 mmol/L, HbA1c 44 mmol/mol, total cholesterol 6.2 mmol/L, triglycerides 3.8 mmol/L. She is psychiatrically stable with good symptom control. What is the most appropriate management of her metabolic complications?
A 48-year-old man with bipolar affective disorder type I is admitted with acute mania. He is verbally aggressive and physically threatening. He has not slept for 4 days and refuses all oral medication. Observations show: HR 110 bpm, BP 165/95 mmHg, temperature 37.4°C. He has no significant physical health problems. What is the most appropriate pharmacological management for rapid tranquilization?
A 36-year-old man with schizophrenia has been taking clozapine 450mg daily for 9 months with good symptom control. He now presents with constipation for 10 days, abdominal distension, vomiting, and absent bowel sounds. Abdominal X-ray shows dilated loops of bowel. What is the most likely underlying mechanism of his presentation?
A 43-year-old woman with rapid-cycling bipolar affective disorder has had 6 mood episodes in the past 12 months despite lithium monotherapy at therapeutic levels. She has a history of polycystic ovary syndrome. Which medication would be most appropriate to add or switch to for optimizing her mood stabilization?
Severe Mental Illness UK Medical PG Practice Questions and MCQs
Question 41: A 27-year-old woman with bipolar affective disorder type I has been stable on lithium carbonate 800mg daily for 2 years. She attends for routine monitoring. Blood tests show: lithium level 0.7 mmol/L, TSH 8.5 mU/L (normal 0.5-5.0), free T4 11 pmol/L (normal 10-20), creatinine 95 μmol/L, eGFR >90 mL/min. She reports feeling more tired than usual but denies other symptoms. What is the most appropriate management?
- A. Stop lithium and switch to sodium valproate
- B. Continue lithium and start levothyroxine replacement (Correct Answer)
- C. Reduce lithium dose to 600mg daily
- D. Continue lithium and monitor thyroid function in 3 months
- E. Continue lithium and refer to endocrinology
Explanation: ***Continue lithium and start levothyroxine replacement*** - The patient has **subclinical hypothyroidism** (elevated **TSH**, normal **fT4**) with symptoms of fatigue, which is a common side effect of **lithium therapy**. - Since the patient is psychiatrically stable on **lithium**, the appropriate management is to continue the mood stabilizer and treat the thyroid dysfunction with **levothyroxine replacement** to alleviate symptoms and prevent progression. *Stop lithium and switch to sodium valproate* - Abruptly stopping **lithium** in a stable patient with bipolar disorder carries a high risk of **psychiatric relapse**, including manic or depressive episodes. - **Sodium valproate** has significant **teratogenic risks** and is generally avoided in women of **childbearing potential** unless absolutely necessary and with strict precautions. *Reduce lithium dose to 600mg daily* - Reducing the **lithium dose** may drop the serum concentration below the **therapeutic range** (0.6–1.0 mmol/L), risking a loss of mood control and psychiatric instability. - Dose reduction is typically not an effective strategy to reverse **lithium-induced hypothyroidism** once established, and it doesn't address the underlying thyroid deficiency. *Continue lithium and monitor thyroid function in 3 months* - The patient is **symptomatic** (fatigue) and has clear biochemical evidence of **subclinical hypothyroidism**; thus, active treatment is warranted rather than just monitoring. - **Lithium-induced thyroid dysfunction** is unlikely to resolve spontaneously while the patient remains on the medication and often requires replacement therapy. *Continue lithium and refer to endocrinology* - **Lithium-induced hypothyroidism** is a common and well-understood side effect that can typically be managed by the treating psychiatrist or general practitioner. - Referral to **endocrinology** is usually reserved for more complex cases, unclear diagnoses, or thyroid dysfunction refractory to standard **levothyroxine replacement**.
Question 42: A 38-year-old man with paranoid schizophrenia has been taking olanzapine 20mg daily for 5 years. He develops increasing social withdrawal, reduced self-care, and loss of motivation over 8 months. Mental state examination reveals flat affect, poverty of speech, and lack of volition. There are no positive psychotic symptoms. What is the most appropriate medication adjustment?
- A. Increase olanzapine to 30mg daily
- B. Add an SSRI antidepressant to current regimen
- C. Switch to amisulpride monotherapy
- D. Add aripiprazole to current olanzapine (Correct Answer)
- E. Switch to clozapine monotherapy
Explanation: ***Add aripiprazole to current olanzapine***- The patient exhibits core **negative symptoms** (avolition, flat affect, poverty of speech) which are effectively targeted by the **partial dopamine agonism** of aripiprazole.- Adding aripiprazole as an **augmentation strategy** can improve negative symptom scores and social functioning without losing control of positive symptoms.*Increase olanzapine to 30mg daily*- Increasing the dose of a **second-generation antipsychotic** typically addresses **positive symptoms** rather than the deficit syndrome observed here.- Higher doses may worsen **secondary negative symptoms** due to increased **sedation** and potentially greater dopamine receptor blockade.*Add an SSRI antidepressant to current regimen*- While useful for co-morbid **depression**, SSRIs are not considered first-line treatments for the **primary negative symptoms** of schizophrenia.- The clinical picture describes typical **schizophrenia-specific deficits** (poverty of speech, lack of volition) rather than a clear depressive episode.*Switch to amisulpride monotherapy*- Although **low-dose amisulpride** has evidence for treating negative symptoms, a complete switch risks the recurrence of **positive psychotic symptoms**.- Managing chronic stable patients usually involves **augmentation** before a complete switch if a specific symptom cluster emerges late in the course.*Switch to clozapine monotherapy*- Clozapine is reserved for **treatment-resistant schizophrenia**, defined as failure of two different antipsychotics at adequate doses.- While it can help negative symptoms, its side effect profile (e.g., **agranulocytosis**, **seizures**) makes it inappropriate as a first step for managing emerging social withdrawal.
Question 43: A 41-year-old woman with schizoaffective disorder has been maintained on depot paliperidone palmitate 150mg monthly for 3 years with good symptom control. She now presents requesting to try for pregnancy. Her mental state remains stable with no active psychotic symptoms. She has previously relapsed rapidly when antipsychotic medication was discontinued. What is the most appropriate advice regarding her medication management?
- A. Continue paliperidone depot throughout pregnancy as benefits outweigh risks
- B. Stop paliperidone immediately and remain unmedicated during pregnancy
- C. Switch to haloperidol oral medication before conception
- D. Switch to quetiapine oral medication before conception (Correct Answer)
- E. Continue paliperidone until pregnancy confirmed, then stop immediately
Explanation: ***Switch to quetiapine oral medication before conception*** - **Quetiapine** is generally considered a safer option for use during pregnancy among antipsychotics, with more established **safety data** and a relatively lower risk of **hyperprolactinemia** compared to paliperidone. - Switching to an **oral medication** allows for greater flexibility in dose adjustment and the ability to discontinue the medication promptly if adverse effects or complications arise during pregnancy, which is not feasible with a **long-acting injectable** (depot). *Continue paliperidone depot throughout pregnancy as benefits outweigh risks* - **Paliperidone depot** has limited human pregnancy data, and its **long-acting nature** means that exposure to the fetus would continue for an extended period, even if complications arose and discontinuation was desired. - The **irreversibility** and prolonged systemic presence of a depot injection make it less ideal for managing the dynamic physiological changes and potential adverse events during pregnancy where immediate therapeutic adjustments might be necessary. *Stop paliperidone immediately and remain unmedicated during pregnancy* - The patient has a clear history of **rapid relapse** upon discontinuation of antipsychotic medication, indicating a high risk of symptom exacerbation if unmedicated. - A psychiatric relapse during pregnancy poses significant risks to both maternal and fetal health, including poor **antenatal care**, self-harm, inadequate nutrition, and potential need for urgent hospitalization, outweighing the risks of medication. *Switch to haloperidol oral medication before conception* - While **haloperidol** has been used in pregnancy for many years, it is a **first-generation antipsychotic** associated with a higher risk of **extrapyramidal side effects** in the mother and potential **neonatal withdrawal symptoms** or neuromuscular disturbances. - **Second-generation antipsychotics** like quetiapine are often preferred due to a generally better **tolerability profile** and lower rates of motor side effects, making them a more suitable choice for long-term management, especially during pregnancy. *Continue paliperidone until pregnancy confirmed, then stop immediately* - Discontinuing an antipsychotic abruptly, especially one like paliperidone with a history of **rapid relapse** upon cessation, significantly increases the risk of a **psychotic episode** during early pregnancy. - Given that paliperidone is a **depot injection**, stopping further injections upon confirmed pregnancy would still result in prolonged drug exposure due to its long half-life, negating the intention of immediate cessation.
Question 44: A 29-year-old man with bipolar affective disorder type I presents to the emergency department with a 2-day history of increasing confusion, fever (39.2°C), muscle rigidity, and profuse sweating. He was started on haloperidol 10mg twice daily 5 days ago for an acute manic episode. Observations show: BP 165/95 mmHg, HR 115 bpm, RR 22/min. Blood tests reveal: CK 8500 U/L, WCC 15.2 × 10⁹/L, creatinine 145 μmol/L. What is the most likely diagnosis?
- A. Serotonin syndrome
- B. Malignant hyperthermia
- C. Neuroleptic malignant syndrome (Correct Answer)
- D. Acute dystonic reaction
- E. Sepsis secondary to pneumonia
Explanation: ***Neuroleptic malignant syndrome***- Characterized by the tetrad of **fever**, **lead-pipe muscle rigidity**, **autonomic instability** (tachycardia, hypertension, sweating), and **altered mental status** following the start of high-potency antipsychotics like **haloperidol**.- Laboratory findings typically show significantly **elevated Creatine Kinase (CK)**, **leukocytosis**, and potential **acute kidney injury** due to rhabdomyolysis.*Serotonin syndrome*- This condition is usually triggered by **selective serotonin reuptake inhibitors (SSRIs)** and is characterized by **hyperreflexia** and **myoclonus**, rather than the rigidity seen in this case.- While it shares some autonomic features, the presentation lacks the extreme elevation of **CK levels** and the specific association with **dopamine antagonists**.*Malignant hyperthermia*- This is a rare, life-threatening reaction that occurs specifically in response to **volatile anesthetic gases** (e.g., halothane) or **succinylcholine**.- The clinical timeline does not fit this patient, as it typically presents in the **operating room** or immediate post-operative period.*Acute dystonic reaction*- Usually presents with sudden, involuntary muscle contractions such as **torticollis** or **oculogyric crisis** shortly after starting an antipsychotic.- It lacks systemic symptoms like **high grade fever**, **sweating**, and severe **lab abnormalities** seen in this presentation.*Sepsis secondary to pneumonia*- While sepsis causes **fever**, **tachycardia**, and **confusion**, it does not explain the profound **generalized muscle rigidity** or the massive **CK elevation**.- The recent initiation of **haloperidol** acts as a specific red flag for a drug-induced emergency rather than a primary infectious process.
Question 45: A 36-year-old man with a 10-year history of bipolar affective disorder type I presents to his psychiatrist. He has had three previous manic episodes requiring hospitalisation. For the past 8 months, he has been stable on lithium carbonate 1200mg daily. His most recent lithium level was 0.9 mmol/L (therapeutic range 0.6-1.0). He now presents with a 4-day history of persistent vomiting and diarrhoea due to gastroenteritis. What is the most appropriate immediate management?
- A. Continue lithium at current dose and check levels in one week
- B. Reduce lithium dose by 50% until gastroenteritis resolves
- C. Temporarily stop lithium and check urgent lithium level (Correct Answer)
- D. Switch to sodium valproate immediately
- E. Continue lithium and prescribe oral rehydration solution
Explanation: ***Temporarily stop lithium and check urgent lithium level*** - Dehydration from **persistent vomiting and diarrhoea** increases the risk of **lithium toxicity** as the kidneys prioritize sodium reabsorption, leading to decreased renal clearance of lithium. - **Lithium** has a **narrow therapeutic index**, and since the patient's level is already at the high end (0.9 mmol/L), the drug should be withheld until the acute illness resolves and levels are reassessed. *Continue lithium at current dose and check levels in one week* - This approach is dangerous because continued dosing during dehydration can lead to **acute-on-chronic lithium toxicity**, which is life-threatening. - Waiting one week for levels is inappropriate as **renal function** and lithium concentration can change drastically within hours in the setting of gastroenteritis. *Reduce lithium dose by 50% until gastroenteritis resolves* - Even a reduced dose can lead to accumulation and toxicity when the patient is in a **hypovolemic state** with impaired excretion. - Clinical guidelines recommend **temporary cessation** during such metabolic disturbances rather than dose adjustment. *Switch to sodium valproate immediately* - This is not the immediate priority; the primary concern is managing the potential for **lithium toxicity** and stabilizing the patient's hydration. - Starting a new **mood stabilizer** while the patient is acutely unwell with gastroenteritis could confound the clinical picture and introduce new side effects. *Continue lithium and prescribe oral rehydration solution* - While rehydration is important, simply adding fluids is insufficient because the patient's **gastrointestinal losses** might still exceed intake, maintaining a toxic state. - **Lithium** must be stopped to eliminate the source of toxicity while the underlying cause of **dehydration** is being treated.
Question 46: A 45-year-old woman with schizophrenia presents to the community mental health team. She has been taking quetiapine 750mg daily for 18 months with good symptom control. Blood tests reveal: HbA1c 58 mmol/mol, fasting glucose 7.8 mmol/L, total cholesterol 6.2 mmol/L, triglycerides 3.4 mmol/L. Her BMI has increased from 24 to 31 kg/m² since starting quetiapine. She has no cardiovascular symptoms. What is the most appropriate next step in management?
- A. Continue quetiapine and refer to dietitian for lifestyle modification
- B. Switch to aripiprazole and refer for metabolic monitoring (Correct Answer)
- C. Add metformin to current regimen and continue quetiapine
- D. Reduce quetiapine dose to 400mg daily
- E. Stop quetiapine immediately and start haloperidol
Explanation: ***Switch to aripiprazole and refer for metabolic monitoring***- The patient presents with established **metabolic syndrome**, including elevated **HbA1c (58 mmol/mol)**, **dyslipidemia**, and significant **weight gain (BMI 24 to 31 kg/m²)**, all attributable to long-term quetiapine use, a **second-generation antipsychotic (SGA)** known for its high metabolic risk. - Switching to an SGA with a **lower metabolic risk profile**, such as **aripiprazole**, which is considered **metabolically neutral**, is the most appropriate intervention to mitigate further metabolic complications while maintaining psychiatric stability. *Continue quetiapine and refer to dietitian for lifestyle modification*- Relying solely on **lifestyle modification** is insufficient given the severity of the established **metabolic abnormalities** (diabetes/pre-diabetes, obesity) while continuing the primary causative agent, **quetiapine**.- This approach does not address the underlying pharmacological cause and risks further progression of **diabetes** and **cardiovascular disease** despite potential lifestyle changes. *Add metformin to current regimen and continue quetiapine*- While **metformin** can aid in managing antipsychotic-induced weight gain and hyperglycemia, it represents an additional **pill burden** and does not remove the primary offending agent, quetiapine.- A **medication switch** to a metabolically safer antipsychotic is generally preferred over adding more drugs when psychiatric symptoms are stable, addressing the root cause more effectively. *Reduce quetiapine dose to 400mg daily*- Reducing the quetiapine dose carries a significant risk of **psychotic relapse** as the patient is currently stable at 750mg daily, and the lower dose may be sub-therapeutic.- Dose reduction is unlikely to reverse the already established and severe **metabolic syndrome** and significant weight gain, which typically requires a change in medication. *Stop quetiapine immediately and start haloperidol*- **Abrupt cessation** of quetiapine can precipitate severe **withdrawal symptoms** and a high risk of **psychotic relapse**, necessitating a gradual **cross-taper** when switching antipsychotics.- **Haloperidol**, a first-generation antipsychotic, has a high propensity for **extrapyramidal symptoms (EPS)** and **tardive dyskinesia**, making it a less favorable choice compared to newer, metabolically neutral SGAs like aripiprazole.
Question 47: A 33-year-old woman with schizophrenia treated with risperidone 6mg daily for 2 years presents to her GP. She has gained 18kg in weight (BMI now 34 kg/m²) and her most recent blood tests show: fasting glucose 6.9 mmol/L, HbA1c 44 mmol/mol, total cholesterol 6.2 mmol/L, triglycerides 3.8 mmol/L. She is psychiatrically stable with good symptom control. What is the most appropriate management of her metabolic complications?
- A. Switch from risperidone to aripiprazole to reduce metabolic effects while maintaining symptom control (Correct Answer)
- B. Continue risperidone and start metformin 500mg twice daily for prediabetes
- C. Continue risperidone and start atorvastatin 20mg daily for dyslipidaemia
- D. Switch from risperidone to ziprasidone which has lower metabolic risk
- E. Reduce risperidone dose to 4mg daily to minimize metabolic side effects
Explanation: ***Switch from risperidone to aripiprazole to reduce metabolic effects while maintaining symptom control*** - **Risperidone** is associated with significant **metabolic side effects** like weight gain, dyslipidaemia, and impaired glucose tolerance, all present in this patient. - **Aripiprazole** has a significantly more favorable **metabolic profile** and is a suitable alternative for a psychiatrically stable patient, addressing the root cause of her metabolic syndrome. *Continue risperidone and start metformin 500mg twice daily for prediabetes* - While **metformin** can aid in glucose control and weight management, it treats the symptoms rather than the underlying **antipsychotic-induced** metabolic burden. - The preferred approach is to change the causative agent, if possible, before adding additional medications for side effect management. *Continue risperidone and start atorvastatin 20mg daily for dyslipidaemia* - **Atorvastatin** will address the dyslipidaemia, but it will not resolve the **weight gain** or **prediabetes** caused by risperidone. - This option increases **polypharmacy** without tackling the primary driver of her overall metabolic complications and cardiovascular risk. *Switch from risperidone to ziprasidone which has lower metabolic risk* - While **ziprasidone** has a low metabolic risk, it often requires **ECG monitoring** for **QTc prolongation**, which can limit its practical use. - **Aripiprazole** is generally considered a first-line option among agents with low metabolic risk due to its broader safety profile and good tolerability. *Reduce risperidone dose to 4mg daily to minimize metabolic side effects* - **Dose reduction** may not be sufficient to reverse or adequately manage established **metabolic syndrome** and carries a risk of **psychiatric relapse**. - The metabolic effects of second-generation antipsychotics are often not solely dose-dependent, making a change to a different antipsychotic a more effective strategy.
Question 48: A 48-year-old man with bipolar affective disorder type I is admitted with acute mania. He is verbally aggressive and physically threatening. He has not slept for 4 days and refuses all oral medication. Observations show: HR 110 bpm, BP 165/95 mmHg, temperature 37.4°C. He has no significant physical health problems. What is the most appropriate pharmacological management for rapid tranquilization?
- A. Intramuscular haloperidol 5mg plus promethazine 50mg (Correct Answer)
- B. Intramuscular lorazepam 2mg alone
- C. Intravenous diazepam 10mg
- D. Intramuscular olanzapine 10mg plus lorazepam 2mg
- E. Intramuscular zuclopenthixol acetate 100mg
Explanation: ***Intramuscular haloperidol 5mg plus promethazine 50mg***- This combination is a recommended first-line option for **rapid tranquilization** in acute agitation, especially when oral medication is refused, due to its effectiveness in controlling aggression and agitation in **acute mania**.- **Promethazine** provides additional sedation and helps to mitigate the **extrapyramidal side effects** (EPS) associated with **haloperidol**, offering a safer profile compared to combining antipsychotics with benzodiazepines.*Intramuscular lorazepam 2mg alone*- While **lorazepam** can provide sedation, it may not be sufficiently effective as **monotherapy** for the profound aggression and agitation seen in severe **acute mania**.- Benzodiazepines alone carry a higher risk of **respiratory depression** when used in high-arousal states compared to an antipsychotic-antihistamine combination.*Intravenous diazepam 10mg*- **Intravenous administration** for rapid tranquilization is generally avoided due to the increased risk of sudden **cardiorespiratory arrest** and the practical difficulties of safe delivery in a physically aggressive patient.- **Diazepam** has a longer half-life and active metabolites, making it less ideal for immediate, controlled behavioral management in a psychiatric emergency compared to shorter-acting agents.*Intramuscular olanzapine 10mg plus lorazepam 2mg*- Combining **intramuscular olanzapine** with **parenteral benzodiazepines** is strictly contraindicated due to a significantly increased risk of severe **cardiorespiratory depression** and profound sedation.- If both are considered necessary, they must be administered with a minimum of **one hour** interval between doses to minimize severe adverse effects.*Intramuscular zuclopenthixol acetate 100mg*- **Zuclopenthixol acetate** (Acuphase) has a **delayed onset of action** (full effect within 2-3 hours) and a prolonged duration (2-3 days), making it unsuitable for **rapid tranquilization** where immediate control is needed.- It is generally reserved for patients with a **known positive response** to the drug and should not be used in **antipsychotic-naïve** individuals or when rapid reversibility is a concern.
Question 49: A 36-year-old man with schizophrenia has been taking clozapine 450mg daily for 9 months with good symptom control. He now presents with constipation for 10 days, abdominal distension, vomiting, and absent bowel sounds. Abdominal X-ray shows dilated loops of bowel. What is the most likely underlying mechanism of his presentation?
- A. Mechanical obstruction from adhesions secondary to clozapine-induced inflammation
- B. Anticholinergic effects causing reduced bowel motility and paralytic ileus (Correct Answer)
- C. Direct toxic effect of clozapine on enteric smooth muscle cells
- D. Clozapine-induced mesenteric ischaemia causing bowel infarction
- E. Bacterial overgrowth syndrome from clozapine-altered gut flora
Explanation: ***Anticholinergic effects causing reduced bowel motility and paralytic ileus*** - **Clozapine** possesses potent **antimuscarinic (anticholinergic)** properties that significantly inhibit the enteric nervous system, leading to reduced peristalsis and gastrointestinal hypomotility. - The clinical triad of **absent bowel sounds**, abdominal distension, and **dilated bowel loops** on imaging characterizes **paralytic ileus**, a potentially life-threatening complication of clozapine therapy. *Mechanical obstruction from adhesions secondary to clozapine-induced inflammation* - This mechanism involves physical barriers like scar tissue; however, clozapine causes a **functional obstruction** (ileus) rather than a mechanical one. - Adhesions typically follow **abdominal surgery** or chronic inflammatory conditions, which are not described in this medication-induced scenario. *Direct toxic effect of clozapine on enteric smooth muscle cells* - While clozapine affects the gut, it does so primarily by blocking **muscarinic receptors** rather than via direct **cytotoxic damage** to smooth muscle histology. - The dysfunction is **pharmacological blockade** of neurotransmission, not a drug-induced myopathy or cellular necrosis. *Clozapine-induced mesenteric ischaemia causing bowel infarction* - Although severe untreated ileus can eventually lead to **intestinal ischemia** due to high intraluminal pressure, it is a secondary consequence rather than the primary mechanism. - **Mesenteric ischemia** usually presents with pain out of proportion to exam findings and risk factors like **atrial fibrillation**, rather than chronic drug-induced constipation. *Bacterial overgrowth syndrome from clozapine-altered gut flora* - While stasis can lead to **Small Intestinal Bacterial Overgrowth (SIBO)**, it does not explain the acute clinical presentation of **bowel obstruction** and absent sounds. - The primary driver of the physical findings is the **neurogenic failure** of the bowel to move contents, not a primary change in the **microbiome profile**.
Question 50: A 43-year-old woman with rapid-cycling bipolar affective disorder has had 6 mood episodes in the past 12 months despite lithium monotherapy at therapeutic levels. She has a history of polycystic ovary syndrome. Which medication would be most appropriate to add or switch to for optimizing her mood stabilization?
- A. Lamotrigine as add-on therapy to lithium (Correct Answer)
- B. Sodium valproate as replacement for lithium
- C. Carbamazepine as add-on therapy to lithium
- D. Olanzapine as add-on therapy to lithium
- E. High-dose lithium aiming for levels of 1.2 mmol/L
Explanation: ***Lamotrigine as add-on therapy to lithium*** - **Lamotrigine** is highly effective for the prevention of **depressive episodes** in **rapid-cycling bipolar disorder** and is a suitable add-on when lithium monotherapy fails. - It has a **favorable metabolic profile** and does not exacerbate **polycystic ovary syndrome (PCOS)** symptoms, unlike other mood stabilizers. *Sodium valproate as replacement for lithium* - **Sodium valproate** carries a significant **teratogenic risk** and is contraindicated or strongly avoided in women of childbearing potential, necessitating a Pregnancy Prevention Programme. - It can cause **weight gain** and worsen metabolic and endocrine disturbances associated with **PCOS**, such as insulin resistance. *Carbamazepine as add-on therapy to lithium* - **Carbamazepine** is a potent **enzyme inducer**, leading to numerous **drug-drug interactions** and requiring careful monitoring of drug levels, complicating long-term management. - While effective, it is generally considered a second-line agent for **rapid cycling** due to its side effect profile and interaction potential compared to lamotrigine. *Olanzapine as add-on therapy to lithium* - **Olanzapine** is associated with significant **metabolic side effects**, including substantial **weight gain** and impaired glucose tolerance, which would negatively impact the patient's existing **PCOS**. - While effective for acute mania, its long-term use for maintenance, especially in patients with metabolic concerns, is often limited by these adverse effects. *High-dose lithium aiming for levels of 1.2 mmol/L* - Aiming for a **lithium level of 1.2 mmol/L** significantly increases the risk of **lithium toxicity**, including renal impairment, tremors, and gastrointestinal distress, without necessarily increasing efficacy for rapid cycling. - When a patient with **rapid cycling** fails therapeutic lithium monotherapy, adding a second mood stabilizer is generally more effective and safer than escalating lithium to potentially toxic levels.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free